Received: 22 October 2019
Accepted: 7 August 2020
First Online: 26 August 2020
Ethics approval and consent to participate
: The study was approved by the local committee of Samsung Medical Center (SMC), Seoul, Republic of Korea (IRB file #200505001 and #201004004), on the use of human samples for experimental studies. Written informed consents were provided by the participants prior to enrollment. All experimental methods abided by the principles of the Helsinki Declaration.
: Do-Hyun Nam is founder & CEO of AIMEDBIO Inc. and hold ownership equity in the company. The terms of this arrangement have been reviewed and approved by the Office of R&BD at Samsung Medical Center, in accordance with its conflict of interest policies. Antonio Iavarone declares a potential financial conflict of interest through consultancy in AIMEDBIO Inc. Nam-Gu Her, Byeongkwi Min, and Hye-Jin Kim are under paid employment by AIMEDBIO Inc. The remaining authors declare that they have no competing interests.